The prospect of a world first, orally administered treatment for diabetic macular oedema and wet age-related macular degeneration (wet-AMD), provides new hope to patients who are resistant to anti-VEGF injections.
Curacle, a Korea-based biopharmaceutical company, has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI), the sister company of Théa, for the development and commercialisation of Curacle’s CU06-RE.
Dr Young Guen Kwon said CU06-RE offers high efficacy and convenience as an oral treatment. “As the world’s first vascular endothelial dysfunction blocker developed with Curacle’s Solvadys platform technology, CU06-RE can be applied to patients whose symptoms have worsened due to resistance to anti-VEGF injections, providing great hope for patients who currently do not have a suitable treatment option.”
Jae Hyeon Ryu, CEO of Curacle said, “Through this strategic and collaborative alliance with Théa, a leading global ophthalmic company, we have been able to accelerate the development of CU06-RE as the world’s first oral treatment and the world’s first vascular endothelial dysfunction blocker”.
Théa and Curacle will closely collaborate on the clinical development of the novel oral drug. Curacle will be responsible for the Phase I and II clinical studies with TOI providing both financial and infrastructure support. Further, under the terms of the agreement, Curacle will retain the marketing rights in all Asian countries while Théa will have the marketing rights in all other countries around the world.
